Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 17/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1961303 | 1.00 | DPP4 (0.61) | DPP4KMT2ALMNAMAPK1CHRM1 | |
| SCHEMBL556114 | 1.00 | DPP4 (0.61) | DPP4KMT2ALMNAMAPK1CHRM1 | |
| SCHEMBL555446 | 0.91 | DPP4 (0.58) | DPP4KMT2ALMNAMAPK1CHRM1 | |
| SCHEMBL555696 | 0.88 | DPP4 (0.63) | DPP4KMT2ALMNAMAPK1CHRM1 | |
| SCHEMBL556457 | 0.87 | DPP4 (0.64) | DPP4KMT2ALMNAMAPK1CHRM1 | |
| SCHEMBL555517 | 0.86 | DPP4 (0.68) | DPP4KMT2ALMNAMAPK1CHRM1 | |
| SCHEMBL556083 | 0.86 | DPP4 (0.61) | DPP4KMT2ALMNAMAPK1CHRM1 | |
| SCHEMBL556236 | 0.86 | DPP4 (0.68) | DPP4KMT2ALMNAMAPK1CHRM1 | |
| SCHEMBL556074 | 0.85 | DPP4 (0.71) | DPP4KMT2ALMNAMAPK1CHRM1 | |
| SCHEMBL556507 | 0.85 | DPP4 (0.73) | DPP4KMT2ALMNAMAPK1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144083-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144083-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | DPP4, DPP3, DPP7 | DPP4 1/4885KMT2A 3439/4885LMNA 3445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.